XOMA Royalty Corporation (NASDAQ:XOMA) Given Consensus Recommendation of “Hold” by Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has received an average recommendation of “Hold” from the five brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $60.60.

A number of analysts recently weighed in on the stock. Benchmark reissued a “buy” rating on shares of XOMA Royalty in a research report on Friday, December 12th. Stifel Nicolaus set a $50.00 target price on XOMA Royalty in a research note on Friday, December 12th. UBS Group set a $76.00 price target on XOMA Royalty in a research note on Tuesday, December 9th. HC Wainwright cut their price objective on XOMA Royalty from $104.00 to $97.00 and set a “buy” rating on the stock in a research report on Thursday, December 11th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th.

Insiders Place Their Bets

In related news, CEO Owen Hughes acquired 100,000 shares of the stock in a transaction on Thursday, December 4th. The stock was bought at an average cost of $25.05 per share, with a total value of $2,505,000.00. Following the transaction, the chief executive officer directly owned 102,000 shares in the company, valued at approximately $2,555,100. This represents a 5,000.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 9.10% of the stock is owned by insiders.

Institutional Trading of XOMA Royalty

Institutional investors and hedge funds have recently modified their holdings of the stock. Woodline Partners LP boosted its holdings in shares of XOMA Royalty by 16.5% in the third quarter. Woodline Partners LP now owns 209,945 shares of the biotechnology company’s stock valued at $8,091,000 after purchasing an additional 29,715 shares during the period. Vanguard Group Inc. grew its position in shares of XOMA Royalty by 4.6% during the 3rd quarter. Vanguard Group Inc. now owns 668,111 shares of the biotechnology company’s stock worth $25,749,000 after buying an additional 29,298 shares in the last quarter. Stonepine Capital Management LLC increased its stake in shares of XOMA Royalty by 17.2% during the second quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock valued at $3,834,000 after buying an additional 22,330 shares during the period. Occudo Quantitative Strategies LP purchased a new position in shares of XOMA Royalty during the second quarter valued at $527,000. Finally, Panagora Asset Management Inc. bought a new stake in shares of XOMA Royalty in the second quarter valued at about $463,000. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty Stock Down 7.4%

Shares of XOMA opened at $24.92 on Friday. The company has a quick ratio of 3.91, a current ratio of 3.91 and a debt-to-equity ratio of 1.07. The business has a fifty day moving average of $27.30 and a 200 day moving average of $31.17. The company has a market cap of $308.51 million, a PE ratio of 33.68 and a beta of 0.86. XOMA Royalty has a 52-week low of $18.35 and a 52-week high of $39.92.

XOMA Royalty (NASDAQ:XOMA) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.33). The firm had revenue of $9.35 million during the quarter, compared to analysts’ expectations of $11.47 million. XOMA Royalty had a net margin of 32.28% and a return on equity of 2.91%. On average, sell-side analysts expect that XOMA Royalty will post -1.41 EPS for the current year.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.